Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
HTGM HTG Molecular Diagnostics
4.130-0.110-2.59%
Close
01/30 16:00 ET
High
4.300
Open
4.170
Turnover
544.17K
Low
4.020
Pre Close
4.240
Volume
131.17K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Celyad Oncology SA (NASDAQ:CYAD) jumped 187% to $2.30 after gaining 21% on Friday. Celyad Oncology, last month, decided to discontinue the development of its remaining clinical program CYAD-21
Sibanye Stillwater, IQIYI, Bed Bath & Beyond Among Premarket Losers' Pack
12 Health Care Stocks Moving In Monday's After-Market Session
GainersNymox Pharmaceutical (NASDAQ:NYMX) stock moved upwards by 20.7% to $0.52 during Monday's after-market session. The market value of their outstanding shares is at $47.2 million. First Wave BioPh
12 Health Care Stocks Moving In Friday's Intraday Session
GainersTC BioPharm (Holdings) (NASDAQ:TCBP) stock rose 90.6% to $8.5 during Friday's regular session. As of 12:30 EST, TC BioPharm (Holdings)'s stock is trading at a volume of 2.7 million, which is 35
ZyVersa, Jasper Top Healthcare Gainers; Biora, Acer Among Losers
HTG Provides a Year-End Update on Its Drug Discovery Business And Attends LifeSci Partners 2023 Corporate Access Event
TUCSON, Ariz., Jan. 09, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide p
H.C. Wainwright Reaffirms Their Buy Rating on HTG Molecular Diagnostics (HTGM)
HTG Molecular Diagnostics Sees 2022 Rev $6.4M >HTGM
HTG Announces Certain Preliminary 2022 Unaudited Financial Results
Preliminary full year 2022 unaudited revenue of $6.4 million Cash and cash equivalents of $12.2 million as of December 31, 2022 TUCSON, Ariz., Jan. 06, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc.
GE, ENVX and KALA Among Pre Market Losers
Company Overview
More
HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. It serves the biopharmaceutical companies, academic research centres, and molecular testing laboratories. Its proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.
CEO： Mr. John L. Lubniewski
Market： NASDAQ
Listing Date： 05/06/2015
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet